Company: NCEL
Filing Date: 2025-10-17
Form Type: POS AM
Source: 0001213900-25-099986
Chunk: 64

Company: NewcelX Ltd.
Filing Date: 2025-10-17
Form: POS AM
Chunk 64
---
 consultants’ expenses   |     | $ |  104,814 |     | $ |      110,345 |
| Stamp tax                            |     |   |  112,965 |     |   |      125,793 |
| Accrued board fees                   |     |   |   73,021 |     |   |       47,586 |
| Other accrued expenses               |     |   |   16,902 |     |   |       27,554 |
| Accrued dividends on preferred share |     |   |  126,367 |     |   |            — |
| Total other accrued liabilities      |     | $ |  434,069 |     | $ |      311,278 |

Note 5 Commitments and Contingencies: Commitments On March 10, 2021, the Company entered into a license agreement with Novartis Pharma AG (“Novartis”), whereby the Company obtained, on an exclusive basis in the U.S., all of the available data referred to and included in the original new drug application (“NDA”) for Sanorex® (mazindol) submitted to the U.S. Food and Drug Administration (“FDA”) in February 1972. The agreement encompasses all preclinical and clinical studies, data used for manufacturing including stability and other chemistry manufacturing and controls data, formulation data and know -howfor all products containing mazindol as an active substance, and all post -marketingclinical studies and periodic safety reports from 1973 onwards. Under the agreement, the Company has obtained the same rights on a non -exclusivebasis in all territories outside of the U.S. except for Japan, with the right to cross -referencethe Sanorex NDA with non -U.S. regulatory agencies in the licensed territories. The agreement includes the right to sublicense or assign the license to third parties, subject to such third parties meeting certain obligations. As consideration for the license, the Company paid Novartis $ 250,000upon the signing of the agreement with milestone payments due as follows: (i) $750,000 payable following the end of a Phase II meeting with the FDA, with the amount to be reduced to $375,000 if toxicology studies must be repeated; (ii) $2 million following the earlier of FDA marketing authorization of Quilience or Nolazol; (iii) 1% of any upfront and milestone payments, if any, from any sublicensees